Newron Pharmaceuticals S.p.A. (SWX:NWRN)
Switzerland
· Delayed Price · Currency is CHF 14.80
-0.28 (-1.86%)
Apr 29, 2026, 5:30 PM CET
Newron Pharmaceuticals Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 12.19 | 6.93 | 6.34 | 13.42 | 25.02 | Upgrade
|
| Short-Term Investments | 16.69 | 2.89 | 6.26 | 9.35 | 9.58 | Upgrade
|
| Cash & Short-Term Investments | 28.88 | 9.83 | 12.6 | 22.77 | 34.59 | Upgrade
|
| Cash Growth | 193.87% | -22.01% | -44.68% | -34.17% | 10.70% | Upgrade
|
| Accounts Receivable | 2.54 | 42.12 | 2.02 | 1.94 | 1.31 | Upgrade
|
| Other Receivables | 3.62 | 4.94 | 3.16 | 3.03 | 2.74 | Upgrade
|
| Receivables | 6.16 | 47.06 | 5.18 | 4.97 | 4.05 | Upgrade
|
| Prepaid Expenses | 3.04 | 4.22 | 1.87 | 0.75 | 0.78 | Upgrade
|
| Total Current Assets | 38.08 | 61.1 | 19.65 | 28.49 | 39.43 | Upgrade
|
| Property, Plant & Equipment | 0.74 | 0.83 | 0.41 | 0.53 | 0.58 | Upgrade
|
| Other Intangible Assets | 0 | - | - | - | 0 | Upgrade
|
| Other Long-Term Assets | 1.24 | 1.97 | 5.81 | 8.18 | 10.48 | Upgrade
|
| Total Assets | 40.06 | 63.91 | 25.87 | 37.2 | 50.49 | Upgrade
|
| Accounts Payable | 2.32 | 2.47 | 2.02 | 1.91 | 1.5 | Upgrade
|
| Accrued Expenses | 3.4 | 4.94 | 3.49 | 2.17 | 1.1 | Upgrade
|
| Current Portion of Long-Term Debt | 37.46 | 13.41 | 22.28 | - | - | Upgrade
|
| Current Portion of Leases | 0.12 | 0.14 | 0.18 | 0.17 | 0.15 | Upgrade
|
| Other Current Liabilities | 6.83 | 2.55 | 0.97 | 0.79 | 0.9 | Upgrade
|
| Total Current Liabilities | 50.13 | 23.51 | 28.93 | 5.04 | 3.65 | Upgrade
|
| Long-Term Debt | - | 36.24 | 25.75 | 45.17 | 42.54 | Upgrade
|
| Long-Term Leases | 0.58 | 0.67 | 0.21 | 0.33 | 0.39 | Upgrade
|
| Pension & Post-Retirement Benefits | 0.48 | 0.46 | 0.41 | 0.47 | 0.58 | Upgrade
|
| Other Long-Term Liabilities | - | 1.57 | 0.47 | 0.22 | 0.21 | Upgrade
|
| Total Liabilities | 51.19 | 62.45 | 55.77 | 51.23 | 47.38 | Upgrade
|
| Common Stock | 4 | 3.99 | 3.57 | 3.57 | 3.57 | Upgrade
|
| Additional Paid-In Capital | - | - | - | - | 5.1 | Upgrade
|
| Retained Earnings | -18.27 | 10.69 | -21.4 | -22.81 | -20.12 | Upgrade
|
| Comprehensive Income & Other | 3.13 | -13.22 | -12.08 | 5.21 | 14.55 | Upgrade
|
| Shareholders' Equity | -11.14 | 1.46 | -29.91 | -14.03 | 3.11 | Upgrade
|
| Total Liabilities & Equity | 40.06 | 63.91 | 25.87 | 37.2 | 50.49 | Upgrade
|
| Total Debt | 38.16 | 50.47 | 48.42 | 45.66 | 43.08 | Upgrade
|
| Net Cash (Debt) | -9.29 | -40.64 | -35.82 | -22.89 | -8.49 | Upgrade
|
| Net Cash Per Share | -0.47 | -1.98 | -2.01 | -1.28 | -0.48 | Upgrade
|
| Filing Date Shares Outstanding | 20.01 | 19.96 | 17.85 | 17.85 | 17.85 | Upgrade
|
| Total Common Shares Outstanding | 20.01 | 19.96 | 17.85 | 17.85 | 17.85 | Upgrade
|
| Working Capital | -12.05 | 37.6 | -9.27 | 23.45 | 35.77 | Upgrade
|
| Book Value Per Share | -0.56 | 0.07 | -1.68 | -0.79 | 0.17 | Upgrade
|
| Tangible Book Value | -11.14 | 1.46 | -29.91 | -14.03 | 3.11 | Upgrade
|
| Tangible Book Value Per Share | -0.56 | 0.07 | -1.68 | -0.79 | 0.17 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.